Laura J. Rasmussen-Torvik

Nov 1, 2024 | jci.org | Laura J. Rasmussen-Torvik

Editor's noteOpen Access | 10.1172/JCI184350 Published inVolume 134, Issue 21onNovember 1, 2024J Clin Invest. 2024;134(21):e184350. https://doi.org/10.1172/JCI184350. © 2024 Rasmussen-TorvikThis work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Jun 10, 2024 | psychiatrist.com | Hannah K. Betcher |Laura J. Rasmussen-Torvik |Amy Yang |Tatiana Abramova

AbstractObjective: The effectiveness of antidepressant treatment for mood disorders is often limited by either a poor response or the emergence of adverse effects. These complications often necessitate multiple drug trials. This clinical challenge intensifies during pregnancy, when medications must be selected to improve the likelihood of response and optimize reproductive outcomes.